Therapeutic drug monitoring of lopinavir in human immunodeficiency virus-infected children receiving adult tablets

Pediatric Infectious Disease Journal

Volumn 29, Issue 1, 2010, Pages 79-82

  Puthanakit, Thanyawee ^a,b   Chokephaibulkit, Kulkanya ^c   Suntarattiwong, Piyarat ^d   Gorowara, Meena ^a   Vanprapar, Nirun ^c   Leawsrisuk, Pimsiri ^d   Suwanlerk, Tulathip ^a   Boonrak, Pitch ^a   Ruxrungtham, Kiat ^a,b  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Children; Generic drug tablets; HIV; Lopinavir; Therapeutic drug monitoring

Indexed keywords

LOPINAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CHILD; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TABLET FORMULATION; TREATMENT OUTCOME;

EID: 74049099818     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181b21040     Document Type: Article

References (15)

1. The working group on antiretroviral therapy. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://www. Aidsinfo.nih.gov. Accessed February 23, 2009.
2. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44:401-410.
3. Cawthorne P, Ford N, Wilson D, et al. Access to drugs: the case of Abbott in Thailand. Lancet Infect Dis. 2007;7:373-374.
4. Puthanakit T, Oberdorfer A, Akarathum N, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. Clin Infect Dis. 2005;41:100-107.
5. Chokephaibulkit K, Plipat N, Cressey TR, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine, and nevirapine. AIDS. 2005;19:1495-1499.
6. Droste JA, Verweij Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopi-navir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit. 2003;25:393-399.
7. Solas C, Poizot Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse tran-scriptase inhibitor. Br J Clin Pharmacol. 2004;57:436-440.
8. Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J. 2005;24:874-879.
9. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310.
10. Kaletra (Lopinavir And Ritonavir) Film Coated Tablets, Oral Solution. North Chicago, IL: Abbot Laboratories; 2008.
11. van der Lugt LJ, Gorowara M. Bioavailability of generic lopinavir/ritonavir in HIV-infected individuals. Post presented at: 10th International Workshop on Clinical Pharmacology of HIV Therapy; April 15-17, 2009; Amsterdam, Netherlands. Poster number 41.
12. King JR, Acosta EP, Yogev R, et al. Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. Pediatr Infect Dis J. 2009;28:159-161.
13. van der Flier M, Verweel G, van der Knaap LC, et al. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily. Antivir Ther. 2008;13:1087-1090.
14. Gonzalez de Requena D, Blanco F, Garcia Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS. 2003;17:443-445.
15. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ ritonavir-containing regimens. J Acquir Immune Defic Syndr. 2003;33: 594-600.